Cathie Wood Names CRISPR Therapeutics Top 2025 Stock Pick

Cathie Wood's ARK Investment Management is focusing on high-tech firms, with CRISPR Therapeutics AG (CRSP) being a notable part of her portfolio as highlighted in the latest 'Big Ideas 2025' report. Despite a challenging year where CRSP has seen a 36.46% loss, Wood remains optimistic about the future of AI and biotechnology, which she believes could transform industries. The stock's recent performance has been volatile, with a current trading price of approximately $41.10 and a 52-week range between $36.52 and $91.10. Investors are exploring options for CRSP, with a put contract at a $40 strike price showing potential value. The broader implications of Wood's investment strategy and CRSP's performance reflect ongoing debates about the viability of high-risk, high-reward investments in the current market climate. Nevertheless, Wood's funds have shown substantial returns in the past, contributing to her reputation as a tech visionary amidst skepticism from detractors.